Clinical practice considerations and review of the literature for the use of DPP-4 inhibitors in patients with type 2 diabetes and chronic kidney disease

Endocrine Practice

Volumn 19, Issue 6, 2013, Pages 1025-1034

  Ramirez, German ^a   Morrison, Anthony ^b   Bittle, Polly ^a,c  

^a Tampa Bay Rays   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF TAMPA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LINAGLIPTIN; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

ACUTE KIDNEY FAILURE; ANEMIA; AREA UNDER THE CURVE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG USE; ERYTHROCYTE LIFESPAN; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEPATOBILIARY SYSTEM; HUMAN; HYPOGLYCEMIA; KIDNEY CLEARANCE; KIDNEY FAILURE; KIDNEY FUNCTION; LACTIC ACIDOSIS; LONG TERM EXPOSURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRESCRIPTION; REVIEW; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY EXCRETION;

ADAMANTANE; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; NITRILES; PIPERIDINES; PURINES; PYRAZINES; PYRROLIDINES; QUINAZOLINES; RENAL INSUFFICIENCY, CHRONIC; TRIAZOLES; URACIL;

EID: 84888876440     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP12306.RA     Document Type: Review

References (77)

1. Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs. 2011; 71:1441-1467.
2. Jax T. Treatment of patients with diabetes with GLP-1 analogues or DPP-4-inhibitors: a hot topic for cardiologists? Clin Res Cardiol. 2009;98:75-79.
3. Hung AM, Roumie CL, Greevy RA, et al. Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney Int. 2012;81:698-706.
4. Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab. 2011;12:57-69.
5. Reilly JB, Berns JS. Selection and dosing of medications for management of diabetes in patients with advanced kidney disease. Semin Dial. 2010;23:163-168.
6. O'Toole SM, Fan SL, Yaqoob MM, Chowdhury TA. Managing diabetes in dialysis patients. Postgrad Med J. 2012;88:160-166.
7. Banerji MA, Purkayastha D, Francis BH. Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study. Diabetes Res Clin Pract. 2010;90:182-190.
8. Mudaliar S, Chang AR, Aroda VR, et al. Effects of intensive insulin therapy alone and with added pioglitazone on renal salt/water balance and fluid compartment shifts in type 2 diabetes. Diabetes Obes Metab. 2010;12:133-138.
9. DiaBeta(r) (glyburide) prescribing information. Bridgewater, NJ: Sanofi-Aventis US LLC. Available at: http://www. accessdata.fda.gov/drugsatfda- docs/label/2009/017532s 030lbl.pdf. Accessed May 20, 2013.
10. Levemir(r) (insulin detemir) rDNA injection prescribing information. Princeton, NJ: Novo Nordisk Inc. Available at: http://www.novo-pi.com/levemir. pdf. Accessed May 20, 2013.
11. Meyers JL, Candrilli SD, Kovacs B. Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad Med. 2011;123:133-143.
12. Karim A, Fleck P, Hetman L, et al. Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment (abstract 538-P). Presented at: American Diabetes Association 68th Annual Scientific Sessions; June 6-10, 2008; San Francisco, CA.
13. Fujii Y, Abe M, Higuchi T, et al. The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Expert Opin Pharmacother. 2013;14:259-267.
14. Nesina(r) (alogliptin) prescribing information. Deerfield, IL: Takeda Pharmaceuticals Company America, Inc. Available at: https://www.takedadiabetes. com/?gclid=CLr0m8nIuroCFa47MgodynYAeg. Accessed October 28, 2013.
15. Tradjenta(r) (linagliptin) prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc. Available at: http://bidocs. boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase= renetnt&folderPath=/Prescribing+Information/PIs/Tradjenta/Tradjenta.pdf. Accessed May 20, 2013.
16. Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin†. Diabetes Obes Metab. 2011;13:939-946.
17. Friedrich C, Emser A, Woerle HJ, Graefe-Mody U. Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes. Am J Ther. 2013 Feb 13 [Epub ahead of print].
18. Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of b-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011;13:258-267.
19. Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380:475-483.
20. Sloan L, Newman J, Sauce C, et al. Safety and efficacy of linagliptin in type 2 diabetes patients with severe renal impairment (abtract 413?PP). Presented at: 71st Scientific Session of the American Diabetes Association; June 24-28, 2011; San Diego, CA.
21. Cooper M, Von Eynatten M, Emser A, Patel S, Woerle HJ. Efficacy and safety of linagliptin in patients with type 2 diabetes with or without renal function decline: results from a global phase 3 program (poster 1068-P). Presented at: 71st Scientific Sessions of the American Diabetes Association; June 24-28, 2011; San Diego, CA.
22. McGill JB, Sloan L, Newman J, et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care. 2013;36: 237-244.
23. Boulton DW, Li L, Frevert EU, et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet. 2011;50:253-265.
24. Onglyza(r) (saxagliptin) prescribing information. Princeton, NJ: Bristol-Myers Squibb. Available at: http://packageinserts.bms.com/pi/pi-onglyza. pdf. Accessed May 7, 2013.
25. Nowicki M, Rychlik I, Haller H, et al. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab. 2011;13:523-532.
26. Nowicki M, Rychlik I, Haller H, et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract. 2011;65:1230-1239.
27. Bergman AJ, Cote J, Yi B, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care. 2007;30:1862-1864.
28. Januvia(r) (sitagliptin) tablets prescribing information. Whitehouse Stattion, NJ: Merck & Co Inc. Available at: http://www.merck.com/product/ usa/pi-circulars/j/januvia/januvia-pi.pdf. Accessed May 20, 2013.
29. Chan JC, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008; 10:545-555.
30. Kao DP, Kohrt HE, Kugler J. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. Diabet Med. 2008;25:1229-1230.
31. Boucher BJ. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. But what about the amiodarone? Diabet Med. 2009;26:192-193.
32. Pendergrass M, Fenton C, Haffner SM, Chen W. Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis. Diabetes Obes Metab. 2012;14:596-600.
33. European public assessment report (EPAR) summary: Galvus(r) (vildagliptin). London: European Medicines Agency (EMEA). Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the- public/human/000771/WC500020328.pdf. Accessed May 20, 2013.
34. Galvus(r) (vildagliptin) prescribing information. Novartis. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000771/WC500020327.pdf. Accessed May 20, 2013.
35. Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab. 2011;13:947-954.
36. Ligueros-Saylan M, Foley JE, Schweizer A, Couturier A, Kothny W. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab. 2010;12:495-509.
37. Metformin hydrochloride (generic) prescribing information. Sellersville, PA: Teva Pharmaceuticals. Available at: http://www.drugs.com/pro/metformin. html#LINK-702257cc-ad56-42ea-9d8f-e0fdbc564cd0. Accessed May 20, 2013.
38. Shaw JS, Wilmot RL, Kilpatrick ES. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabetes Med. 2007;24:1160-1163.
39. McCormack J, Johns K, Tildesley H. Metformin's contraindications should be contraindicated. CMAJ. 2005;173: 502-504.
40. Fantus IG. Metformin's contraindications: needed for now. CMAJ. 2005;173:505-507.
41. Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention. Drug Saf. 2010;33:727-740.
42. Nye HJ, Herrington WG. Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract. 2011;118:c380-383.
43. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006; CD002967.
44. Scheen AJ, Paquot N. Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab. 2013;39:179-180.
45. Duong JK, Kumar SS, Kirkpatrick CM, et al. Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function. Clin Pharmacokinet. 2013;52: 373-384.
46. Sharif A. Metformin for patients with diabetes and concomitant renal restrictions-is there an evidence base? QJM. 2013;106:291-294.
47. Yang T, Soodvilai S. Renal and vascular mechanisms of thiazolidinedione-induced fluid retention. PPAR Res. 2008; 2008:943614.
48. Glimepiride (generic) prescribing information. Sellersville, PA: Teva Pharmaceuticals. Available at: http://www.drugs.com/pro/glimepiride.html. Accessed May 20, 2013.
49. Glipizide (generic) tablets USP prescribing information. Sellersville, PA: Teva Pharmaceuticals. Available at: http://www.drugs.com/pro/glipizide.html. Accessed May 20, 2013.
50. Holmes CJ. Reducing cardiometabolic risk in peritoneal dialysis patients: role of the dialysis solution. J Diabetes Sci Technol. 2009;3:1472-1480.
51. Collins AJ, Foley RN, Chavers B, et al. United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis. 2012;59:e1-420.
52. Kazempour-Ardebili S, Lecamwasam VL, Dassanyake T, et al. Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes. Diabetes Care. 2009; 32:1137-1142.
53. Cohen RM, Franco RS, Khera PK, et al. Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood. 2008;112:4284-4291.
54. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173:534-539.
55. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141:150-156.
56. Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011;27 Suppl 3:57-64.
57. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care. 2010;33:2349-2354.
58. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009;25:1019-1027.
59. Williams-Herman D, Round E, Swern AS, et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord. 2008;8:14.
60. The Endocrine Society. Risk of pancreatitis associated with certain diabetes medications: an Endocrine Society statement. Available at: https://www.endo crine.org/~/media/endosociety/Files/Advocacy%20and%20Outreach/ Position%20Statements/All/TheEndocrineSocietyStatementontheRiskof PancreatitisinPatientsTreatedwithGLP1basedTherapies.pdf Accessed May 20, 2013.
61. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
62. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
63. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
64. Molyneaux LM, Constantino MI, McGill M, Zilkens R, Yue DK. Better glycaemic control and risk reduction of diabetic complications in Type 2 diabetes: comparison with the DCCT. Diabetes Res Clin Pract. 1998;42:77-83.
65. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
66. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
67. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358:2560-2572.
68. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.
69. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-139.
70. Abraira C, Colwell JA, Nuttall FQ, et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care. 1995;18:1113-1123.
71. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23 Suppl 2:B21-29.
72. Buehler AM, Cavalcanti AB, Berwanger O, et al. Effect of tight blood glucose control versus conventional control in patients with type 2 diabetes mellitus: a systematic review with meta-analysis of randomized controlled trials. Cardiovasc Ther. 2013;31:147-160.
73. Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos. 2010;38:667-678.
74. He H, Tran P, Yin H, et al. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos. 2009;37: 536-544.
75. Arjona Ferreira JC, Marre M, Barzilai N, et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care. 2013;36:1067-1073.
76. Arjona Ferreira JC, Corry D, Mogensen CE, et al. Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. Am J Kidney Dis. 2013;61:579-587.
77. Lukashevich V, Schweizer A, Foley JE, Dickinson S, Groop PH, Kothny W. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment. Vasc Health Risk Manag. 2013;9:21-28.